(Adds detail)
LONDON, Dec 24 (Reuters) - AstraZeneca (AZN.L) said the U.S. Food and Drug Administration (FDA) had requested further information relating to a supplemental new drug application for its schizophrenia drug Seroquel.
The Anglo-Swedish drugmaker said on Wednesday it was evaluating the contents of a so-called “complete response letter” from the FDA and proposed labelling revisions.
It said it will continue discussions with the FDA and provide a response to the agency in due course. (Reporting by Matt Scuffham)
